# Varinos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/varinos

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.varinos.com
- Total disclosed funding: $7.3M
- Latest round: Series D (Mar 31, 2026)
- Investors on record: 10

## About

Founded in 2017 by CEO Sakuraba and co-founder Nagai and based in Tokyo, Japan, Varinos Inc., d.b.a Varinos, a startup specializing in genome analysis. The company develops and offers clinical tests that leverage genomic technology for infertility treatments in reproductive medicine, dental care abroad, and personalized medicine. In March 2026, Varinos Inc. raised an undisclosed amount ?in?series D funding led by Miraisozo Investments and Resona Bank, with participation from Mitsui Chemicals, Yokohama Capital, Shizuoka Bank, Shoko Chukin Bank, Joyo Bank and Higashi-Nippon Bank. The round was part of a larger JPY 1.25 billion series D and debt funding.

Varinos???? specializes in the development and clinical implementation of genetic testing solutions utilizing advanced genomic technologies. The company's core product offerings include a range of genetic tests focused on infertility, reproductive health, and microbiome analysis, particularly uterine flora assessments and preimplantation genetic testing. These services aim to address societal issues such as infertility and declining birth rates by providing personalized insights that assist families in making informed decisions regarding their reproductive health. Varinos serves healthcare providers, fertility clinics, and individual consumers, delivering tailored genomic information that aids in understanding and interpreting specific genetic results. The company markets its products primarily within Japan, with potential outreach to other regions as it expands its base of operations.The revenue model of Varinos???? is structured around direct-to-consumer sales and B2B partnerships with healthcare providers and fertility clinics. Clients engage with the firm through purchasing specific genetic testing services or partnering for comprehensive analysis solutions. Transactions typically involve individual payments for services rendered, such as uterine flora tests and preimplantation genetic tests, tailored to the unique needs of each client. Pricing structures are designed to provide accessible solutions for different consumer segments while ensuring high-quality and precise testing outcomes. Additionally, ongoing collaborations with medical professionals enhance the company's outreach and service offerings, reinforcing its position in the reproductive health market.

The company plans to use the March 2026 funding to grow new businesses, expand market share locally and internationally, and improve testing quality.

## Funding rounds

- Series D, Mar 31, 2026 — Yokohama Capital, Mitsui Chemicals, Miraisozo Investments
- Series C, Aug 3, 2022, $4.4M — Mitsubishi UFJ Capital, SMBC Venture Capital, Miyako Capital, Fast Track Initiative, Sony Innovation Fund, Angel Bridge, MTG Ventures
- Series B, Sep 25, 2020, $2.9M — SMBC Venture Capital, Miyako Capital, Angel Bridge

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B, Series C
- Miyako Capital (https://capitalatlas.ai/funds/miyako-capital) — Series B, Series C
- Angel Bridge (https://capitalatlas.ai/funds/angel-bridge) — Series B, Series C
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series C
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Series C
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Series C
- MTG Ventures (https://capitalatlas.ai/funds/mtg-ventures) — Series C
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series D
- Mitsui Chemicals — Series D
- Miraisozo Investments (https://capitalatlas.ai/funds/miraisozo-investments) — Series D